^
Association details:
| Biomarker: | RAB22A underexpression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug Class: | Bcl2 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
3338 RAB22A As a Predictor of Exosome Secretion in the Progression and Relapse of Multiple Myeloma
Published date:
11/02/2023
Excerpt:
We screened sensitive drugs according to the difference of IC50 values between high and low RAB22A groups, and found that cisplatin, Doxorubicin and bcl-2 inhibitors had higher sensitivity in low RAB22A group.
